Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims about muscle and liver monitoring with interacting agents (including strong CYP3A4 inhibitors and grapefruit juice) are consistent with the provided label sections. However, multiple statements broaden “supplements” beyond the label’s described concomitant drugs, and several patient-action/urgency and symptom-specific escalation instructions (e.g., “urgent medical care,” “dark urine,” “fatigue/unwell,” “don’t stop without medical advice,” “every supplement name and label dose”) are not explicitly supported by the provided label excerpts.
Category Scores
Accurate Statements
Grapefruit is a known concern with some statins because it can raise statin exposure.
7.2 Grapefruit Juice; 17.1 Muscle Pain (risk increased with >1 liter grapefruit juice).
Statin liver-related effects can include elevated liver enzymes detected on blood work.
5.2 Liver Dysfunction (persistent elevations of serum transaminases; LFTs recommended/monitoring).
Unsupported Statements
Combining atorvastatin with supplements that stress the liver can raise the chance of abnormal liver blood tests.
No provided label language supports supplements “that stress the liver” as a driver of abnormal LFTs; the excerpt focuses on biochemical abnormalities, monitoring, and caution/contraindications related to alcohol/substantial quantities and history of liver disease.
If a supplement contributes to muscle injury on its own, adding a statin (atorvastatin) may increase the risk of muscle-related side effects.
The provided excerpts do not state that supplements can cause muscle injury on their own or that atorvastatin risk increases based on supplement-specific injury mechanisms.
Fatigue or feeling unwell can occur as a statin side effect.
The provided excerpts reference malaise only as an accompaniment to muscle symptoms; they do not explicitly list fatigue/feeling unwell as an adverse effect on its own in the shown sections.
If a person develops dark urine, fever, or severe weakness alongside muscle symptoms, they should seek urgent medical care.
No provided label language mentions “dark urine” or gives an explicit urgent-care instruction for this symptom combination.
A person should not stop Lipitor without medical advice.
The provided excerpts include clinician-directed discontinuation guidance for myopathy/CPK, but do not include the specific patient instruction phrased as “should not stop ... without medical advice.”
A person should tell their clinician every supplement name (and the label dose), not just the category.
The provided label advises discussing prescription and over-the-counter medication and informing clinicians of atorvastatin use; it does not instruct patients to provide every supplement name and label dose.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Boxed warning content (if any) was not present in the supplied label excerpts; boxed-warning adherence cannot be assessed.
Importance:
Moderate
Contraindication details beyond the liver-function excerpt (e.g., contraindications section not provided) were not assessed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Risk stems from patient-action statements using stronger urgency and supplement-generalization not explicitly supported by the provided label text (e.g., “urgent medical care,” supplement category broadening, and symptom-specific escalation like “dark urine”). While the core monitoring concepts for muscle symptoms (report promptly) and liver enzyme testing (before/after initiation and dose increases) are supported, unsupported patient directives could lead to miscalibrated actions relative to the label’s wording.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims generalize from label-supported concomitant drugs (including strong CYP3A4 inhibitors and grapefruit juice) to “supplements” broadly, and several patient-counseling statements use urgency/symptom-specific triggers not explicitly provided in the provided label excerpts.
Suggested Improvement
Restrict wording to the label-supported scope: cite “concomitant drugs”/specific CYP3A4 inhibitors and grapefruit juice; use label-consistent phrasing such as “report promptly” rather than “urgent medical care” unless the provided label excerpt states that; avoid unsupported symptom triggers (e.g., “dark urine”); align patient messaging about discussing prescription and OTC medications and informing clinicians, without adding supplement-name-and-dose requirements not present in the excerpt.